NewsRoom Articles - Page 76 of 222

ThursdayJul 13, 2023 1:12 pm

Observational Study Finds Minimal Patient Participation in Eczema Clinical Trials

Data shows that 1 in 10 Americans is currently living with eczema, a topical condition that reduces the skin’s barrier function and leads to the formation of itchy, dry bumps on the skin. Although eczema patients can use several remedies to alleviate most eczema symptoms, the condition currently has no cure. Despite this, an observational study has found that few patients choose to participate in eczema clinical trials despite the possibility of deriving significant benefits from new investigational therapies. According to the study, taking part in eczema clinical trials can provide better treatment options and opportunities to people with the…

WednesdayJul 12, 2023 12:12 pm

Study Links Gut Flora to Onset of Pediatric Rheumatism

The human body comprises many complex and interconnected systems that rely on and affect each other in myriad ways. One of the most complex systems is the gut biome, a collection of bacteria that live in the digestive tract and have a symbiotic relationship with humans. The gut biome is made up of trillions of bacteria, fungi and viruses that aid digestion and affect immunity, brain and heart health. Researchers from the University of Florida and Linköping University have found that children who suffer from rheumatism exhibit differences in their gut biome compared to healthy children up to 10 years…

WednesdayJul 12, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline

The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a…

TuesdayJul 11, 2023 2:22 pm

Five Challenges Healthcare eCommerce May Face

Healthcare companies around the globe are adopting technology at an accelerated pace and are predicted to spend trillions on the adoption of medical technology by 2040. However, the fledgling healthcare e-commerce segment will have to overcome several challenges to get off the ground. Ensuring data security will be one of the first major challenges as healthcare providers handle extremely sensitive data on a regular basis. But as more patient information is provided online and kept on computer systems, the risk of cyberattacks increases significantly. In 2021 alone, data breaches in the healthcare segment affected up to 45 million people. Healthcare…

MondayJul 10, 2023 11:48 am

Study Suggests Skin Moles Could Provide Treatment for Hair Loss

Data from the American Hair Loss Association estimates that about two-thirds of men may experience various forms of hair loss by age 35 and 85% of men will have considerable thinning hair by age 50. Hair loss also affects women, with around 40% of women expected to experience some visible hair loss by age 40. Although there are several medications that can halt hair growth and encourage the growth of thinning hair, they often have to be taken in perpetuity to keep hair loss at bay. Consequently, there is ongoing research on therapies that could permanently treat hair loss without…

MondayJul 10, 2023 9:00 am

Genprex Inc. (NASDAQ: GNPX) Reports Positive Results from its Phase 1 Acclaim-1 Clinical Trial; Releases Patient Video Describing Positive Experience

Genprex recently announced that its lead drug candidate, REQORSA(R), was well tolerated with no dose-limiting toxicities in the Phase 1 portion of its Acclaim-1 clinical trial The Phase 1 clinical data were added to by the release of a new patient video highlighting a patient’s experience with REQORSA. This patient has now been on the Acclaim-1 trial without disease progression for one year The Safety Review Committee approved the advancement of the Acclaim 1 clinical trial to the Phase 2 expansion portion of the trial Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients…

FridayJul 07, 2023 11:04 am

Biochemist Working to Make Chemo Sans Side Effects

Although cancer treatments have come quite a long way in terms of improving health outcomes and post-diagnosis expectancy rates, treatment is rarely ever pleasant. Most cancer patients who undergo treatments such as chemotherapy will experience side effects including hair loss, anemia, infections, nausea, loss of appetite, fatigue, bruising and bleeding. In many cases, these symptoms can be so severe that patients have to take additional steps to alleviate the side effects of chemotherapy. Biochemist Liyan Zhang is working to develop a chemotherapy drug that can deliver the benefit without subjecting patients to severe side effects. Zhang notes that while chemotherapy…

ThursdayJul 06, 2023 2:47 pm

Study Concludes That Long COVID Should Be Treated Holistically

Although the world is through the worst of the coronavirus pandemic and most of the population has moved on from the disease, a small subset of the population still deals with COVID-19 to this day. These are people who are still suffering from symptoms such as insomnia, lightheadedness, extreme fatigue and brain fog due to a condition called long COVID. An April survey by the federal government’s Household Pulse revealed that close to 10% of adults who contracted the communicable disease are still experiencing sustained coronavirus symptoms. Given the novelty of the condition, researchers are still studying long COVID in…

ThursdayJul 06, 2023 9:00 am

Genprex, Inc. (NASDAQ: GNPX) Receives Third Fast Track Designation for REQORSA(R), Setting Stage for Commencement of Acclaim-3 Clinical Trial in Q3

Genprex recently received a Fast Track Designation (“FTD”) from the FDA for its REQORSA(R) Immunogene Therapy in combination with Genentech, Inc.’s Tecentriq(R) in patients with extensive-stage small cell lung cancer This is Genprex’s third FTD and sets the stage for the initiation of its third lung cancer clinical trial, Acclaim-3 Acclaim-3 clinical trial is a Phase 1/2 dose escalation and clinical response study of maintenance therapy evaluating REQORSA in combination with Tecentriq The company expects to enroll the first patient in its Acclaim-3 clinical trial in the third quarter of 2023 Genprex is combining its lead product candidate, REQORSA, with…

WednesdayJul 05, 2023 12:19 pm

How eCommerce Could Help Rebuild Consumer Trust in Healthcare Sector

Surveys have shown that a majority of Americans do not trust the healthcare sector, with only 23% of customers reporting that they fully trust the industry. Given the critical role played by the healthcare industry, it is essential that healthcare providers find better and more efficient ways of rebuilding customer trust. Turning to e-commerce may allow healthcare companies to bridge this gap and provide higher-quality services to patients. The internet and digitization were game changers for commerce in general, and they have completely changed how businesses operate. These days, any entrepreneur worth their salt has an online presence and leverages…